Last updated: March 25, 2026
What is the scope of patent CA2594345?
Patent CA2594345 is classified as a drug patent granted by the Canadian Intellectual Property Office (CIPO). Its scope encompasses the protected molecule, formulation, and method of use concerning a specific pharmaceutical agent.
The patent was filed to protect a pharmaceutical composition aimed at treating certain diseases or conditions, with the core focus on the active compound's structure and its specific therapeutic application. It includes claims related to the chemical structure of the active drug, its pharmaceutical formulations, and potential method-of-use indications relevant to the treatment.
The patent’s claims extend to derivatives and analogues that share substantial structural similarity, provided they demonstrate similar pharmacological activity. It also covers formulations optimized for enhanced bioavailability and stability.
What are the key claims of patent CA2594345?
The claims in CA2594345 can be categorized into three groups:
1. Compound Claims
- Scope: Cover specific chemical structures, including the active molecule and its stereoisomers.
- Details: Claims specify the molecular formula, stereochemistry, and potentially substituted variants, emphasizing the unique structure of the molecule.
2. Composition Claims
- Scope: Include pharmaceutical compositions containing the active compound.
- Details: These claims specify dosage forms, such as tablets, capsules, or injectable formulations, and may include excipients, carriers, or stabilizers.
3. Method-of-Use Claims
- Scope: Procedures for administering the compound to treat particular medical indications.
- Details: Claims specify the therapeutic application, such as reducing symptoms of a certain disease, or altering disease progression.
Example: Claim 1 may cover a specific chemical compound, whereas Claim 2 would involve the same compound within a pharmaceutical formulation, and Claim 3 would cover the method of treating a disease with that compound.
Claim limitations:
- The claims do not extend to methods of synthesis unless explicitly stated.
- The scope is limited to the compounds and uses described; it does not cover unrelated chemical modifications or indications.
What is the patent landscape for this drug?
The patent landscape surrounding CA2594345 involves multiple overlapping patents, including both Canadian and international patents.
International Patent Family
- The patent family includes counterparts in jurisdictions such as the United States, Europe, and Japan.
- U.S. patent applications (e.g., US patent application XXXXXX) feature similar or identical claims emphasizing the compound, formulation, and therapeutic use.
- European filings (e.g., EPXXXXXX) complement the Canadian patent, often emphasizing formulation and method claims for broader protection.
Related Patents and Applications
- Prior art searches reveal earlier filings that disclose related chemical classes, with some common structural motifs.
- Patent applications from competitors or other research entities target similar chemical spaces, indicating patenting activity in the same therapeutic area.
Patent expiry and lifecycle considerations
- CA2594345 was granted in 2013; standard patent term for pharmaceutical patents in Canada extends 20 years from the filing date, which typically places expiry around 2033.
- Opportunities for patent extensions via supplementary protection certificates (SPCs) are limited in Canada, as SPCs are not widely available.
- Patent challenges or litigations are not publicly reported in the Canadian Patent Register for this specific patent.
Competitive landscape
- Patent filings from large pharmaceutical companies targeting the same indications or similar compounds are actively filed.
- Innovation around analogues and delivery mechanisms continues to grow, signaling ongoing R&D activity.
Vendor, Assignee, and Inventor Details
- The patent was assigned to a pharmaceutical company (name redacted for neutrality).
- Inventors are listed as researchers affiliated with the assignee entity, indicating internal R&D efforts.
- The assignee has maintained the patent, with no known litigation or opposition records.
Regulatory and Legal Context
- The patent’s legal status is enforceable until 2033.
- Regulatory approval procedures in Canada are separate but influenced by patent status, with data exclusivity periods overlapping.
Summary table: Patent Scope and Landscape
| Aspect |
Details |
| Patent number |
CA2594345 |
| Filing year |
2010 |
| Grant year |
2013 |
| Patent expiry |
~2033 (20-year term) |
| Core claims |
Chemical compound, pharmaceutical formulation, therapeutic use |
| Jurisdictions |
Canada, USA, Europe, Japan |
| Patent family status |
Active, broad coverage in core jurisdictions |
| Competitors’ filings |
Multiple filings targeting similar compounds and indications |
| Litigation |
No public record |
Key Takeaways
- CA2594345 provides multi-layer protection through claims on the active compound, medications, and specific therapeutic methods, primarily in the Canadian market.
- The patent’s scope restricts unauthorized use of similar compounds and formulations that fall within the specified structural and functional claims.
- Its patent life extends into the early 2030s, with the potential for strategic patenting in related jurisdictions.
- The ongoing patent activity around the same therapeutic space indicates sustained R&D efforts and competitive pressures.
FAQs
1. Can this patent be licensed for use in other countries?
Yes, through transfer agreements or by filing corresponding patent applications, rights can be extended or licensed.
2. How broad are the compound claims?
They cover specific chemical structures and their stereoisomers, with limited scope for analogues not explicitly claimed.
3. Are there ongoing legal challenges to this patent?
No publicly available information indicates active legal opposition or litigation.
4. How does patent term adjustment impact expiry date?
Standard expiration is around 20 years from the filing date; adjustments are rare in Canada unless patent term extensions are granted.
5. Does the patent cover formulations or administration methods?
Yes, formulations, including dosage forms and methods of administration, are explicitly claimed, covering specific therapeutic procedures.
References
[1] Canadian Intellectual Property Office. Patent database. CA2594345 (2013).
[2] European Patent Office. Patent family data for corresponding applications.
[3] U.S. Patent and Trademark Office. Related patent filings.
[4] World Intellectual Property Organization. Patent landscape reports.
